Evidence map›Paper›PMID 28766184›Full record

ArticlePaediatric drugs2018

Frequency and Nature of Adverse Drug Reactions Due to Non-Prescription Drugs in Children: A Retrospective Analysis from the French Pharmacovigilance Database.

Geneviève Durrieu, Mathieu Maupiler, Vanessa Rousseau, Leila Chebane, François Montastruc, Emmanuelle Bondon-Guitton, Jean-Louis Montastruc

Abstract read
PubMed Publisher
In one paragraph

Article in Paediatric drugs, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.2field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Geneviève DurrieuService de Pharmacologie Médicale et Clinique, Centre Midi-Pyrénées de PharmacoVigilance, de Pharmacoépidémiologie et d'Informations sur les Médicaments, Pharmacopôle Midi-Pyrénées, Toulouse University Hospital, UMR1027 INSERM Pharmacoepidemiology Unit, Faculty of Medicine, University of Toulouse, Toulouse, France. genevieve.durrieu@univ-tlse3.fr.
Mathieu MaupilerService de Pharmacologie Médicale et Clinique, Centre Midi-Pyrénées de PharmacoVigilance, de Pharmacoépidémiologie et d'Informations sur les Médicaments, Pharmacopôle Midi-Pyrénées, Toulouse University Hospital, UMR1027 INSERM Pharmacoepidemiology Unit, Faculty of Medicine, University of Toulouse, Toulouse, France.
Vanessa RousseauService de Pharmacologie Médicale et Clinique, Centre Midi-Pyrénées de PharmacoVigilance, de Pharmacoépidémiologie et d'Informations sur les Médicaments, Pharmacopôle Midi-Pyrénées, Toulouse University Hospital, UMR1027 INSERM Pharmacoepidemiology Unit, Faculty of Medicine, University of Toulouse, Toulouse, France.
Leila ChebaneService de Pharmacologie Médicale et Clinique, Centre Midi-Pyrénées de PharmacoVigilance, de Pharmacoépidémiologie et d'Informations sur les Médicaments, Pharmacopôle Midi-Pyrénées, Toulouse University Hospital, UMR1027 INSERM Pharmacoepidemiology Unit, Faculty of Medicine, University of Toulouse, Toulouse, France.
François MontastrucService de Pharmacologie Médicale et Clinique, Centre Midi-Pyrénées de PharmacoVigilance, de Pharmacoépidémiologie et d'Informations sur les Médicaments, Pharmacopôle Midi-Pyrénées, Toulouse University Hospital, UMR1027 INSERM Pharmacoepidemiology Unit, Faculty of Medicine, University of Toulouse, Toulouse, France.
Emmanuelle Bondon-GuittonService de Pharmacologie Médicale et Clinique, Centre Midi-Pyrénées de PharmacoVigilance, de Pharmacoépidémiologie et d'Informations sur les Médicaments, Pharmacopôle Midi-Pyrénées, Toulouse University Hospital, UMR1027 INSERM Pharmacoepidemiology Unit, Faculty of Medicine, University of Toulouse, Toulouse, France.
Jean-Louis MontastrucService de Pharmacologie Médicale et Clinique, Centre Midi-Pyrénées de PharmacoVigilance, de Pharmacoépidémiologie et d'Informations sur les Médicaments, Pharmacopôle Midi-Pyrénées, Toulouse University Hospital, UMR1027 INSERM Pharmacoepidemiology Unit, Faculty of Medicine, University of Toulouse, Toulouse, France.
Inserm · FRObservatoire Midi-Pyrénées · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionStudies that evaluate the safety of non-prescription drugs in children remain scarce.

objectivesThe aim of the present study was to compare adverse drug reactions (ADRs) due to prescription versus non-prescription drugs in children.

methodsWe conducted a retrospective analysis of ADR notifications for a pediatric population (aged <18 years) registered in the French PharmacoVigilance Database (FPVD) between January 1985 and December 2016 by the Midi-Pyrénées PharmacoVigilance Center (in the south of France). We compared ADR profiles according to drug prescription status using a Chi-squared test.

resultsWe included 2218 notifications concerning 3687 ADRs in the study. Non-prescription drugs were involved in 506 notifications (22.8%). Patients were younger in the non-prescription drug group (6.7 ± 5.3 vs. 8.4 ± 5.7 years in the prescription drug group). No difference by sex was found. Neurological ADRs were more frequent with prescription drugs (21.0%) than with non-prescription drugs (14.2%, p = 0.0008), whereas dermatological disorders (37.2 vs. 29.1%, respectively) and general ADRs (30.8 vs. 20.1%, respectively) were more frequent with non-prescription than with prescription drugs (p = 0.0006 and p < 0.0001, respectively). The frequency of "serious" ADRs was higher with prescription drugs than with non-prescription drugs (40.9 vs. 34.2%, p = 0.007). The non-prescription drugs most frequently implicated with serious ADRs were ibuprofen (n = 37; 4.2%), tuberculosis vaccine (n = 23; 2.6%), aspirin (n = 20, 2.3%), and paracetamol (n = 17; 1.9%). ADRs from prescription drugs involved asparaginase (n = 27; 3.1%), immunoglobulins (n = 25; 2.9%), and amoxicillin (n = 23; 2.4%).

conclusionsNon-prescription drugs, usually considered safe, were frequently responsible for ADR notifications. The non-prescription medication most frequently involved in serious ADRs was ibuprofen.

Indexed as

PharmacovigilanceAdverse Drug Reaction Reporting SystemsChildDatabases, FactualDrug-Related Side Effects and Adverse ReactionsFemaleHumansMaleNonprescription DrugsRetrospective StudiesNonprescription Drugs

Identifiers

PMID28766184
OpenAlexW2740093009

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.